Anti-CD3 Antibody Therapy for Type 1 Diabetes Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interventions fail to prevent or delay the onset of clinical type 1 diabetes (T1D) in high-risk individuals before clinical diagnosis, and there is a need for a treatment that can effectively alter the progression to clinical T1D.
Innovation Solution
Administering a prophylactically effective amount of an anti-CD3 antibody, such as teplizumab, to non-diabetic subjects at risk for T1D, along with determining the presence of specific immune markers like TIGIT+KLRG1+CD8+ T-cells, to indicate successful prevention or delay of T1D onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immune interventions are administered, then beta cell function decline is delayed in recent-onset T1D, but prevention of clinical T1D onset in high-risk individuals is not achieved
Solution Approach 1:
The patent applies preliminary action by administering anti-CD3 antibodies (such as teplizumab) to individuals in Stage 1 or Stage 2 before clinical T1D diagnosis occurs. This pre-intervention approach modifies CD8+ T lymphocyte function early in the disease process, preventing or delaying progression to Stage 3 clinical T1D, rather than treating after symptoms appear.
Solution Approach 2:
The patent utilizes parameter changes by monitoring the percentage of TIGIT+KLRG1+CD8+ T-cells as a biomarker to identify responders to anti-CD3 antibody therapy. Individuals with more than 5-10% TIGIT+KLRG1+CD8+ T-cells in their CD3+ T-cell population show successful prevention or delay of clinical T1D, allowing for personalized treatment decisions based on immunological parameters.
2Reliability
If anti-CD3 antibody treatment is administered early in Stage 1 or Stage 2, then progression to clinical T1D may be prevented, but the effectiveness of intervention is unknown without clinical outcome data
Solution Approach 1:
The patent implements feedback by monitoring TIGIT+KLRG1+CD8+ T-cell percentages as an immunological biomarker to assess response to anti-CD3 antibody therapy. This feedback mechanism allows clinicians to determine whether an individual is experiencing successful prevention or delay of clinical T1D, providing real-time information about intervention effectiveness without waiting for long-term clinical outcomes.
3Reliability
If intervention is delayed until clinical diagnosis, then disease progression is evident, but opportunity for prevention is lost
Solution Approach 1:
The patent applies preliminary action by administering anti-CD3 antibodies (such as teplizumab) to individuals in Stage 1 or Stage 2 before clinical T1D diagnosis occurs. This pre-intervention approach modifies CD8+ T lymphocyte function early in the disease process, preventing or delaying progression to Stage 3 clinical T1D, rather than treating after symptoms appear.
Data Source
AI summary
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T-cells, which is indicative of successful prevention or delay of the onset of clinical T1D.